A Phase 1, Open Label, Dose-escalation Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 3BNC117

PHASE1CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2016

Conditions
HealthyHIV
Interventions
BIOLOGICAL

1 mg/kg, single dose IV administration of 3BNC117

1 mg/kg, single dose IV administration of 3BNC117

BIOLOGICAL

3 mg/kg, single dose IV administration of 3BNC117

3 mg/kg, single dose IV administration of 3BNC117

BIOLOGICAL

10 mg/kg, single dose IV administration of 3BNC117

10 mg/kg, single dose IV administration of 3BNC117

BIOLOGICAL

30 mg/kg, single dose IV administration of 3BNC117

30 mg/kg, single dose IV administration of 3BNC117

BIOLOGICAL

10 mg/kg, two doses IV of 3BNC117

10 mg/kg, two IV administrations of 3BNC117 at weeks 0 and 12

BIOLOGICAL

30 mg/kg, two doses IV of 3BNC117

30 mg/kg, two IV administrations of 3BNC117 at weeks 0 and 12

Trial Locations (4)

10065

The Rockefeller University, New York

Weill Cornell Medical Center, New York

50937

University of Cologne, Cologne

02115

Brigham and Women's Hospital, Boston

All Listed Sponsors
collaborator

Weill Medical College of Cornell University

OTHER

collaborator

Brigham and Women's Hospital

OTHER

collaborator

University of Cologne

OTHER

lead

Rockefeller University

OTHER

NCT02018510 - A Phase 1, Open Label, Dose-escalation Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 3BNC117 | Biotech Hunter | Biotech Hunter